GEN Exclusives

More »

GEN News Highlights

More »
Apr 15, 2008

Affymetrix Brings Its Cancer Research Collaboration Program to North America

  • Affymetrix formed an alliance with 25 cancer researchers thereby extending its Collaborations in Cancer Research Program (CCRP) to North America. The original European CCRP was launched in April 2007.

    The program gives investigators access to Affymetrix’ integrated genomics solution. This solution combines copy number data from the SNP Array 6.0 and expression information from the Human Exon 1.0 ST Array to deliver a comprehensive view of the cancer genome. 

    Affymetrix predicts that initial data from various studies will be released in the next three to six months. The company is also partially funding selected research projects that demonstrate clinical utility. The company will additionally help scientists obtain tools and training and provide forums where investigators can exchange knowledge and share best practices.

    Some esearchers included in the North America CCRP are Tak Mak Wah, University of Toronto, Sami Malek, University of Michigan, William Lin, Broad Institute, Marc Ladanyi, Memorial Sloan-Kettering Cancer Center, Robert Schneider, New York University School of Medicine Cancer Institute, Norman Lee, George Washington University Medical Center, John Hassell, McMaster University, Grover Bagby, Oregon Health and Science University, Ian Campbell, Peter MacCallum Cancer Centre, Loic Le Marchand, University of Hawaii, and Benjamin Tycko, Columbia University.

    Affymetrix reports plans to expand the Collaborations in Cancer Research Program across Asia-Pacific later this year.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Patients Access to Experimental Medicines?

More »